[ad_1]
SAN FRANCISCO, June 9, 2019 / PRNewswire / – The First Subbadysis of Renal Data from the Trial Effect of Dapagliflozin on Cardiovascular Thrombolysis Events in Myocardial Infarction (DECLARE-TIMI 58) indicates that dapagliflozin, an oral inhibitor of Glucose cotransporter 2 (SGLT2), decreased renal disease or kidney death in patients with type 2 diabetes (T2DM). The first results of the study, the first study on cardiovascular outcomes to include a large cohort of patients with diabetes risk factors for atherosclerotic cardiovascular disease (ASCVD) and a large number of patients with diabetes with a ASCVD known, were presented today at the American Diabetes Association.® (79th Scientific Sessions of the ADA)® at the Moscone Convention Center San Francisco.
DECLARE-TIMI is a multinational, randomized, double-blind, placebo-controlled phase III-B trial. This is a superiority test designed to test the hypothesis that in patients with T2D, long-term treatment with dapagliflozin will reduce the two main endpoints. : 1) the incidence of cardiovascular death, myocardial infarction or ischemic stroke or 2) the incidence of cardiovascular death or hospitalization for heart failure.
In the first subbadysis of Phase III kidney data, the researchers found a 47% reduction in the relative risk of declining renal function, end-stage renal failure, or kidney death (at the same time). Excluding death from cardiovascular origin) compared to placebo (1.5%). % vs. 2.6%; HR 0.53 [95% CI 0.43-0.66], p <0.0001). The risk of end-stage renal failure or renal death was lower in the dapagliflozin-treated group compared with the placebo group (11%).[0.1%] 27 [0.3%]; HR 0.41 [95% CI 0.20-0.82]; p = 0.012).
The badysis evaluated data from 17,160 patients with T2DM and whose kidney function was primarily preserved, regardless of the underlying ASCVD. Diabetes patients are six to 12 times more likely to develop end-stage renal disease and twice as likely to develop chronic kidney disease (CKD). Although ESRD was a rare event in the trial, dapagliflozin significantly reduced the incidence compared to placebo (0.1% vs. 0.3%, respectively). Acute kidney injury occurred in 1.5% and 2.0% of the dapagliflozin and placebo groups, respectively. Patients treated with dapagliflozin had less clinically relevant renal outcomes, regardless of eGFR category or urinary albumin-creatinine ratio (UACR), whether they had an established ASCVD risk factor or multiple CV factors.
"Drugs such as dapagliflozin should also be considered as first-line treatment in patients without established cardiovascular disease, they have a high safety margin and should be used regularly by primary care physicians," he said. Itamar Raz, MD, professor of internal medicine at the Hadbadah Medical School of Hebrew University of Jerusalem, head of the Israel National Diabetes Council and former head of the diabetes unit at Hadbadah University Hospital.
The results were presented with further results on the DECLARE-TIMI 58 kidneys, including positive results from an badysis that dapagliflozin was able to both reduce and prevent aggravation of RCU, a key marker of renal health, in all categories of RCU and regardless of the patient's initial referral. . An additional economic badysis on health suggested that early use of dapagliflozin may reduce the costs of treating chronic kidney disease compared to placebo.
Researchers recruited more than 17,000 patients from 882 sites in 33 countries. The trial was conducted independently, in collaboration with academic researchers from the TIMI study group (Boston, United States) and the Hadbadah Hebrew University Medical Center (Jerusalem, Israel). The full results of today's study are available online at The Diabetes Lancet & Endocrinology.
Raz or Leiter, the lead investigators, please contact the ADA Press Office at the following address: From San Francisco Moscone Convention Center on June 7-11, by phone at 415-978-3606 or by email at [email protected].
The 79th Scientific Sessions of the American Diabetes Association, the world's largest scientific meeting dedicated to diabetes research, prevention and care, takes place June 7 to 11, 2019at the Moscone Center in San Francisco, California. Nearly 15,000 physicians, scientists, health professionals and industry representatives from around the world gathered at scientific sessions to present cutting-edge research, treatment recommendations and advances toward diabetes treatment . During this five-day meeting, attendees have exclusive access to more than 850 presentations and 2,000 original research presentations, engage in stimulating and stimulating discussions with leading diabetes experts, and earn continuing education credits. (FMC) or Continuing Education (CE) for educational sessions. The program is divided into eight thematic areas: Acute and Chronic Complications; Behavioral medicine, clinical nutrition, education and exercise; Clinical / Therapeutic Diabetes; Epidemiology / genetics; Immunology / Transplantation; Action of insulin / molecular metabolism; Integrated Physiology / Obesity; and islet biology / insulin secretion. Gretchen Youssef, MS, RDN, CDE, chair of health care and education, delivered his speech titled "It's all about access!", The Saturday, June 8, and Louis H. Philipson, MD, PhD, FACP, President of Medicine and Science, gave his lecture entitled "Precision Medicine: Addressing the Many Faces of Diabetes", the Sunday, June 9. Join the conversation of scientific sessions on social media using # ADA2019.
About the American Diabetes Association
Every day, more than 4,000 people are diagnosed with diabetes in America. Nearly 115 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the country's leading volunteer health organization that fights to counter the diabetes epidemic and help people living with diabetes to flourish. For nearly 80 years, the ADA has been leading discoveries and research to treat, manage and prevent diabetes while working tirelessly for healing. We help people with diabetes to thrive by fighting for their rights and developing programs, advocacy and education to improve their quality of life. Diabetes has brought us together. What we do next will make us connected for life. For more information or to get involved, visit our website at diabete.org or call 1-800-DIABETES (1-800-342-2383). The information is available in English and Spanish. Join the fight with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).
Contact:
Michelle Kirkwood
(703) 299-2053
[email protected]
SOURCE American Diabetes Association
Related Links
http://www.diabetes.org
[ad_2]
Source link
